Eli Lilly (LLY)
746.37
-19.58 (-2.56%)
NYSE · Last Trade: Aug 6th, 9:37 PM EDT
Detailed Quote
Previous Close | 765.95 |
---|---|
Open | 756.56 |
Bid | 753.50 |
Ask | 754.00 |
Day's Range | 740.19 - 763.00 |
52 Week Range | 677.09 - 972.53 |
Volume | 4,759,177 |
Market Cap | 713.96B |
PE Ratio (TTM) | 60.73 |
EPS (TTM) | 12.3 |
Dividend & Yield | 6.000 (0.80%) |
1 Month Average Volume | 3,576,855 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The Danish pharmaceutical company is fighting a competitive war on several fronts.
Via The Motley Fool · August 6, 2025
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?
Via The Motley Fool · August 6, 2025
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.
Via Benzinga · August 6, 2025
The company is struggling with several headwinds as it works to develop its obesity plan.
Via Investor's Business Daily · August 6, 2025
Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped.
Via The Motley Fool · August 6, 2025
The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk.
Via Investor's Business Daily · August 6, 2025
Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
Via Benzinga · August 6, 2025
The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.
Via Stocktwits · August 6, 2025
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.
Via Benzinga · August 6, 2025
Global pharmaceutical company Eli Lilly (NYSE:LLY)
will be reporting earnings this Thursday before the bell. Here’s what investors should know.
Via StockStory · August 5, 2025
The company, which went public in May, provides AI-powered physical therapy through a mobile application.
Via Investor's Business Daily · August 5, 2025
Are you brave enough to catch this falling knife?
Via The Motley Fool · August 5, 2025
Inspire Medical stock falls as Q2 earnings beat is overshadowed by guidance cut and slower U.S. rollout of its newly approved Inspire V system.
Via Benzinga · August 5, 2025
Whether you're looking for growth stocks, dividend stocks, or artificial intelligence stocks, there is something for you in this incredible list.
Via The Motley Fool · August 5, 2025
Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings
Via MarketBeat · August 5, 2025
The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug.
Via Investor's Business Daily · August 5, 2025
A significant trading signal flashed for Eli Lilly (LLY) at a price of $755.87, after which LLY rose up to 1.8% and closed near its intra-day high.
Via Benzinga · August 5, 2025
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.
Via Benzinga · August 5, 2025
It's not too late to invest in this company.
Via The Motley Fool · August 4, 2025
Via Benzinga · August 4, 2025
This weight loss drugmaker may be significantly undervalued right now.
Via The Motley Fool · August 4, 2025
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics.
Via Benzinga · August 4, 2025
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Via MarketMinute · August 4, 2025
Here are hot stocks to buy in a hot month.
Via The Motley Fool · August 2, 2025
Zepbound could benefit handsomely if an apparently planned government program is implemented.
Via The Motley Fool · August 1, 2025